Cite
HARVARD Citation
Vitiello, P. et al. (n.d.). 18PCombination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four consensus molecular subtypes. Annals of oncology. p. . [Online].